Mechanisms of hypoxia-mediated immune escape in cancer

IB Barsoum, M Koti, DR Siemens, CH Graham - Cancer research, 2014 - AACR
Cancer research, 2014AACR
An important aspect of malignant progression is the acquired ability of tumor cells to avoid
recognition and destruction by the immune system (immune escape). Clinical cancer
progression is also associated with the development of tumor hypoxia, which is
mechanistically linked to the acquisition of malignant phenotypes in cancer cells. Despite
the well-established role of hypoxia in tumor cell invasion and metastasis, and resistance to
therapy, relatively few studies have examined the contribution of hypoxia to cancer immune …
Abstract
An important aspect of malignant progression is the acquired ability of tumor cells to avoid recognition and destruction by the immune system (immune escape). Clinical cancer progression is also associated with the development of tumor hypoxia, which is mechanistically linked to the acquisition of malignant phenotypes in cancer cells. Despite the well-established role of hypoxia in tumor cell invasion and metastasis, and resistance to therapy, relatively few studies have examined the contribution of hypoxia to cancer immune escape. Accumulating evidence reveals that hypoxia can impair anticancer immunity by altering the function of innate and adaptive immune cells and/or by increasing the intrinsic resistance of tumor cells to the cytolytic activity of immune effectors. Here, we discuss certain aspects of the contribution of hypoxia to tumor immune escape and provide evidence for a novel role of cyclic guanosine monophosphate (cGMP) signaling in the regulation of hypoxia-induced immune escape. Thus, we propose that activation of cGMP signaling in cancer cells may have important immunotherapeutic applications. Cancer Res; 74(24); 7185–90. ©2014 AACR.
AACR